Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2022-04-26 | Garry Neil, M.D. was nominated for election to our Board of Directors in March 2022. Since February 2022, Dr. Neil has served as Chief Executive Officer at Avalo Therapeutics (formerly Cerecor, Inc.), a publicly held biotechnology company. ... Dr. Neil holds a B.S. from the University of Saskatchewan and an M.D. from the University of Saskatchewan College of Medicine. |
| 2023-04-25 | Garry A. Neil, M.D. 69 2022 2 The Board of Directors has established a Nominating and Corporate Governance Committee currently consisting of Herbert J. Conrad, Chair, Cheryl L. Cohen and Garry Neil, M.D. The following table summarizes the annual compensation for our non-employee directors during 2022. Garry A. Neil, M.D. Fees Earned or Paid in Cash ($) 34,185 Option Awards ($) 463,733 Total ($) 497,918 |
| 2024-04-25 | The Board of Directors has established a Nominating and Corporate Governance Committee currently consisting of Herbert J. Conrad, Chair, Rita Jain, M.D. and Garry Neil, M.D. ... The Board of Directors has established a Science and Regulatory Committee currently consisting of Garry Neil, M.D., Chair, Cheryl L. Cohen and Rita Jain, M.D. ... The amounts in the Option Awards column reflect the grant date fair value in accordance with U.S. GAAP of stock option awards made in 2023 to each of our non-employee directors for awards pursuant to the 2021 Incentive Plan subject to a vesting schedule whereby an equal number of the shares of common stock shall become vested and no longer be subject to risk of forfeiture (so long as the director remains a member of the Board as of such date). |
Data sourced from SEC filings. Last updated: 2025-08-30